Stay updated on Pembrolizumab+Lenvatinib vs Chemo in Endometrial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Lenvatinib vs Chemo in Endometrial Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Lenvatinib vs Chemo in Endometrial Carcinoma Clinical Trial page
- Check6 days agoChange DetectedThe page now shows Revision: v3.5.3, replacing the previous v3.5.2. This indicates the study history record has been updated to a newer version.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedFooter Revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed from the record history.SummaryDifference0.0%

- Check56 days agoChange DetectedA new revision entry v3.4.3 was added to the history, and the previous v3.4.2 entry was removed.SummaryDifference0.0%

- Check85 days agoChange DetectedAdded Revision: v3.4.2 to the history. Removed notices about government funding lapse and NIH Clinical Center operating status (Revision: v3.4.1).SummaryDifference0.3%

- Check92 days agoChange DetectedA new revision (v3.4.1) was added, introducing core study sections such as Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Eligibility, Arms and Interventions, Study Status, and Study Identification, replacing the previous revision (v3.4.0).SummaryDifference0.7%

Stay in the know with updates to Pembrolizumab+Lenvatinib vs Chemo in Endometrial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Lenvatinib vs Chemo in Endometrial Carcinoma Clinical Trial page.